HomeCLLS • NASDAQ
Cellectis SA
add
Financials
Income Statement
Revenue
Net Income
Revenue
Net income
| (USD) | Jun 2025info | Y/Y change |
|---|---|---|
Revenue | 18.19M | 91.44% |
Operating expense | 27.78M | 3.99% |
Net income | -23.74M | 6.07% |
Net profit margin | -130.46 | 50.93% |
Earnings per share | -0.22 | 18.52% |
EBITDA | -6.46M | 55.36% |
Effective tax rate | — | — |
Balance Sheet
Total Assets
Total Liabilities
Total assets
Total liabilities
| (USD) | Jun 2025info | Y/Y change |
|---|---|---|
Cash and short-term investments | 59.81M | -59.87% |
Total assets | 353.97M | -13.06% |
Total liabilities | 256.86M | -0.65% |
Total equity | 97.11M | — |
Shares outstanding | 72.33M | — |
Price to book | 1.93 | — |
Return on assets | -6.67% | — |
Return on capital | -11.97% | — |
Cash Flow
Net Change in Cash
Net change in cash
| (USD) | Jun 2025info | Y/Y change |
|---|---|---|
Net income | -23.74M | 6.07% |
Cash from operations | -10.31M | -119.76% |
Cash from investing | -52.72M | 50.47% |
Cash from financing | -4.27M | -105.44% |
Net change in cash | -67.83M | -360.16% |
Free cash flow | -23.11M | 16.32% |
Previous close
$2.59
Day range
$2.53 - $2.64
Year range
$1.10 - $3.24
Market cap
190.37M USD
Avg Volume
209.70K
P/E ratio
-
Dividend yield
-
About
Cellectis is a French biopharmaceutical company. It develops genome-edited chimeric antigen receptor T-cell technologies for cancer immunotherapy. It has offices in Paris, New York City, and Raleigh, North Carolina. Wikipedia
Founded
1999
Website
Employees
219
